PubMed:19082449 JSONTXT

{"project":"bionlp-st-cg-2013-training","denotations":[{"id":"T1","span":{"begin":25,"end":84},"obj":"Gene_or_gene_product"},{"id":"T2","span":{"begin":99,"end":104},"obj":"Organism"},{"id":"T3","span":{"begin":105,"end":122},"obj":"Cancer"},{"id":"T4","span":{"begin":124,"end":183},"obj":"Gene_or_gene_product"},{"id":"T5","span":{"begin":185,"end":194},"obj":"Gene_or_gene_product"},{"id":"T6","span":{"begin":300,"end":309},"obj":"Gene_or_gene_product"},{"id":"T7","span":{"begin":335,"end":340},"obj":"Organism"},{"id":"T8","span":{"begin":341,"end":361},"obj":"Cell"},{"id":"T9","span":{"begin":459,"end":468},"obj":"Gene_or_gene_product"},{"id":"T10","span":{"begin":483,"end":500},"obj":"Cancer"},{"id":"T11","span":{"begin":555,"end":564},"obj":"Gene_or_gene_product"},{"id":"T12","span":{"begin":568,"end":585},"obj":"Cancer"},{"id":"T13","span":{"begin":676,"end":685},"obj":"Gene_or_gene_product"},{"id":"T14","span":{"begin":715,"end":732},"obj":"Cancer"},{"id":"T15","span":{"begin":766,"end":775},"obj":"Gene_or_gene_product"},{"id":"T16","span":{"begin":779,"end":784},"obj":"Organism"},{"id":"T17","span":{"begin":785,"end":810},"obj":"Tissue"},{"id":"T18","span":{"begin":824,"end":838},"obj":"Tissue"},{"id":"T19","span":{"begin":855,"end":872},"obj":"Cancer"},{"id":"T20","span":{"begin":873,"end":881},"obj":"Organism"},{"id":"T21","span":{"begin":949,"end":958},"obj":"Gene_or_gene_product"},{"id":"T22","span":{"begin":1076,"end":1084},"obj":"Organism"},{"id":"T23","span":{"begin":1090,"end":1096},"obj":"Cancer"},{"id":"T24","span":{"begin":1128,"end":1137},"obj":"Gene_or_gene_product"},{"id":"T25","span":{"begin":1226,"end":1235},"obj":"Gene_or_gene_product"},{"id":"T26","span":{"begin":1308,"end":1314},"obj":"Multi-tissue_structure"},{"id":"T27","span":{"begin":1325,"end":1349},"obj":"Gene_or_gene_product"},{"id":"T28","span":{"begin":1351,"end":1354},"obj":"Gene_or_gene_product"},{"id":"T29","span":{"begin":1422,"end":1431},"obj":"Gene_or_gene_product"},{"id":"T30","span":{"begin":1489,"end":1498},"obj":"Gene_or_gene_product"},{"id":"T31","span":{"begin":1565,"end":1574},"obj":"Gene_or_gene_product"},{"id":"T32","span":{"begin":1623,"end":1640},"obj":"Cancer"}],"text":"Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer.\nChicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer."}